NISHITH.TV
  • Mumbai
  • Silicon Valley
  • Bengaluru
  • Singapore
  • Mumbai BKC
  • New Delhi
  • New York

Locations

  • Mumbai
  • Silicon Valley
  • Bengaluru
  • Singapore
  • Mumbai BKC
  • New Delhi
  • New York
  • Content
  • Home
  • ABOUT US
  • NDA in the Media
  • Areas of Service
  • Research and Articles
  • Opportunities
  • Contact
  • NDACloud
  • Client Access
  • Member Access
  • Events and Calendar
  • How we perform
  • Knowledge anywhere, anytime
  • See our recent deals
  • Transactional insights unlocked
  • Up to date legal developments
  • Case studies in M&A

M&A Lab

HTMLPDF

April 7, 2009

Sun Pharma - Taro Pharma Deal Dissection

What kicked off as a friendly outbound acquisition by an Indian company is now being fought as a battle in the court room. This is one battle which has shaken the two top pharma corporates of the world and has taken them through a roller coaster ride. One of India’s leading drug maker Sun Pharmaceutical Industries Limited (“Sun India”) would have expanded its base to include another giant drug making company of Israel i.e. Taro Pharmaceutical Industries Limited (“Taro Israel”) by way of a reverse triangular merger. Strikingly, what was supposed to be the second largest outbound acquisition by an Indian company in the pharma space is now into disputed waters.

Sun India intended to acquire Taro Israel with the vision to increase its portfolio, strengthen its position in USA and get an entry into the European markets. The parties executed a series of agreements to accord their understanding of the merger and also provided for a back-up arrangement to counter the situation if the merger fails.

However, Taro Israel witnessed a financial turnaround converting it from a company in losses to a profit yielding enterprise which as Sun India contends may be because of its injection of suitable amount of funding into Taro Israel by releasing Taro Israel from its debt. This financial turnaround raised the expectations of Taro Israel claiming that Sun India’s offer was unjust and did not reflect the real worth of the company.

It would be interesting to understand the factors attributable to the said behavior of the parties. This M&A Lab dissects the commercial, legal, regulatory and tax aspects with respect to India, Israel, Hungary and U.S.A. For the sake of convenience and better understanding, this M&A Lab is divided into 2 parts – (Part A) Pre termination of Merger Agreements; and (Part B) Post termination of Merger Agreements.


For a detailed analysis of the commercial, legal, regulatory & tax considerations, please click here for the document.


As you would be aware, we have been providing regular information on latest legal developments. M&A Lab is our latest initiative to provide you in depth and knowledge based analysis of latest M&A deals. We will be happy to have your views / comments on our initiative. Please read the disclaimer carefully.


– Abir Roy, Sambhav Ranka & Nishchal Joshipura 
You can direct your queries or comments to Team M&A

 

INTERESTING READ

FLÄKT (INDIA) LIMITED, FLÄKTWOODS GROUP, HAS ACQUIRED THE AIR MANAGEMENT SYSTEMS08-01-2020
FLÄKT (INDIA) LIMITED, FLÄKTWOODS GROUP, HAS ACQUIRED THE AIR MANAGEMENT SYSTEMS08-01-2020

Mission and Vision


Distinctly Different

What's New


Beyond Reasonableness: Delhi HC’s Strict Scrutiny of Post-Employment Restraints
HR Law Hotline: July 03,2025
Mid-Year FPI Wrap 2025: Developments in The Foreign Portfolio Investor Regime
Regulatory Hotline : July 01,2025

Events


Webinars

Designing Innovative Share Swap and Deferred Consideration Structures for PE and M&A Deals
July 15,2025 - July 15,2025

Seminar

Guided Meditations by Dr. Deepak Chopra
December 14,2024 - December 14,2024

This event is over. For event material please click here


Round Table

Investing In Net Zero
July 22,2022 - July 22,2022

This event is over. For event material please click here

News Roundup


News Articles

2025 Watchlist: Life Sciences Sector India
April 04,2025

Quotes

Can Indian Companies Compete with MNCs in GLP-1 Production?
July 01,2025

Newsletters


HR Law Hotline

Beyond Reasonableness: Delhi HC’s Strict Scrutiny of Post-Employment Restraints
July 03,2025

Regulatory Hotline

Mid-Year FPI Wrap 2025: Developments in The Foreign Portfolio Investor Regime
July 01,2025

Technology Law Analysis

Over the horizon technologies and legal innovation: emerging use cases for India Inc
July 01,2025

  • Disclaimer
  • Content
  • Feedback
  • Walkthrough
  • Subscribe
Nishith Desai Associates@2016 All rights reserved.